Investors weren’t buying Valeant boss Joseph Papa’s promises of a “new Valeant” Tuesday morning. Despite beating analyst estimates, shares of the beleaguered pharmaceutical giant fell as much 10 percent after the company reported fourth quarter and full year 2016 results. Although Valeant’s headline numbers beat expectations, analysts saw reasons to remain skeptical. “It still doesn’t...
read more
Source: New York Post